All News
Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO
Olga Petryna DrPetryna ( View Tweet)
Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x
Richard Conway RichardPAConway ( View Tweet)
BE COMPLETE study:
Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals.
Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy
Dr. Rachel Tate uptoTate ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Lab Domains:
LAC not always feasible to recheck
aCL, aB2GP IgG higher risk, higher titers (>40U)
@RheumNow https://t.co/rcQaqrtDN5
Eric Dein ericdeinmd ( View Tweet)
The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt
Dr. Rachel Tate uptoTate ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL
Richard Conway RichardPAConway ( View Tweet)
#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
Olga Petryna DrPetryna ( View Tweet)
RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL
Dr. Rachel Tate uptoTate ( View Tweet)
Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae
Richard Conway RichardPAConway ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Obstetric domain redefined
Added:
⭐️Cardiac thickening/vegetation
⭐️Thrombocytopenia
@Rheumnow https://t.co/Me2jrnvalU
Eric Dein ericdeinmd ( View Tweet)
Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA
Dr. Rachel Tate uptoTate ( View Tweet)
Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Uggh!
What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE
TheDaoIndex KDAO2011 ( View Tweet)
Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F
Dr. Rachel Tate uptoTate ( View Tweet)
Lower socioeconomic status (cluster 1) patients:
● older age at the diagnosis (37.9 vs. 32.6)
● longer diagnosis delay (7.8 vs. 6.8 years)
● higher BMI (27.6 vs. 25.9)
● greater structural damage
vs cluster 2
Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw
Dr. Antoni Chan synovialjoints ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Novel Aspects
Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles
Microvasc - Suspected/Established
@RheumNow https://t.co/M8NWRSyH4p
Eric Dein ericdeinmd ( View Tweet)
#abs1235 #acr22 @rheumnow
articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
Olga Petryna DrPetryna ( View Tweet)
PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
Dr. Rachel Tate uptoTate ( View Tweet)